0.00Open0.00Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover0.00%IV136.41%PremiumMay 17, 2024Expiry Date5.77Intrinsic Value100Multiplier-5DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Puma Biotechnology Stock Discussion
Puma Biotechnology Inc - Jury Found '314 & '162 Patents to Be Infringed by AstraZeneca and Not Invalid, Awarded Plaintiffs $107.5 Mln in Damages
loading...
• The study named ALISCA-Breast1 is designed to evaluate alisertibin combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn’t undergone chemotherapy.
• ...
7 MINUTES AGO, 8:30 AM EST
VIA BUSINESSWIRE
No comment yet